Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 5
2004 1
2005 7
2006 2
2007 1
2008 2
2009 3
2010 1
2011 2
2012 3
2013 6
2014 2
2015 4
2016 4
2017 2
2018 1
2019 1
2020 1
2021 3
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Among authors: bilinska m. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Among authors: bilinska m. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.
Cantilevers: Multi-Tool in Orthodontic Treatment.
Bilinska M, Kristensen KD, Dalstra M. Bilinska M, et al. Dent J (Basel). 2022 Jul 19;10(7):135. doi: 10.3390/dj10070135. Dent J (Basel). 2022. PMID: 35877409 Free PMC article. Review.
Craniofacial shape from pre- to post-adolescence.
Maciejewska-Turek A, Bilińska M, Wellens HLL, Fudalej PS. Maciejewska-Turek A, et al. Among authors: bilinska m. Eur J Orthod. 2022 May 24;44(3):332-339. doi: 10.1093/ejo/cjab061. Eur J Orthod. 2022. PMID: 34458910
Distinctive sphingolipid patterns in chronic multiple sclerosis lesions.
Podbielska M, Szulc ZM, Ariga T, Pokryszko-Dragan A, Fortuna W, Bilinska M, Podemski R, Jaskiewicz E, Kurowska E, Yu RK, Hogan EL. Podbielska M, et al. Among authors: bilinska m. J Lipid Res. 2020 Nov;61(11):1464-1479. doi: 10.1194/jlr.RA120001022. Epub 2020 Aug 7. J Lipid Res. 2020. PMID: 32769146 Free PMC article.
[Seronegative myasthenia gravis].
Bilińska M. Bilińska M. Pol Merkur Lekarski. 2002 Jan;12(67):49-53. Pol Merkur Lekarski. 2002. PMID: 11957803 Polish.
Neuropsychological assessment in myasthenia gravis.
Sitek EJ, Bilińska MM, Wieczorek D, Nyka WM. Sitek EJ, et al. Among authors: bilinska mm. Neurol Sci. 2009 Feb;30(1):9-14. doi: 10.1007/s10072-008-0001-y. Epub 2009 Jan 16. Neurol Sci. 2009. PMID: 19148573
58 results